Drug Type Small molecule drug |
Synonyms 4',5,7-trihydroxyisoflavone, 5,7,4'-trihydroxyisoflavone, 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one + [8] |
Mechanism Protein-tyrosine kinases inhibitors, Top II inhibitors(Topoisomerase II inhibitors), Apoptosis stimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationFast Track (US) |
Molecular FormulaC15H10O5 |
InChIKeyTZBJGXHYKVUXJN-UHFFFAOYSA-N |
CAS Registry446-72-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lung Injury | Phase 2 | US | 27 Apr 2022 | |
Pulmonary Fibrosis | Phase 2 | US | 11 Nov 2020 | |
Osteoporosis | Phase 2 | CN | 11 Apr 2017 | |
Leukemia | Phase 2 | CA | 01 Jul 2015 | |
Advanced Malignant Solid Neoplasm | Phase 2 | CA | 01 Nov 2012 | |
Non-Small Cell Lung Cancer | Phase 2 | CA | 01 Nov 2012 | |
Adenocarcinoma of prostate | Phase 2 | US | 01 Dec 2011 | |
Adenocarcinoma | Phase 2 | SE | 01 Nov 2010 | |
Breast Cancer | Phase 2 | US | 01 Jan 2006 | |
Bladder Cancer | Phase 2 | - | - |
Phase 2 | 4 | Placebo+Genistein (Arm A: Genistein Followed by Placebo) | zyeqwagvva(tlbbcinyej) = qstgnpdgsn fnjuenfzzd (kqfvyxookf, dikkcqfhcj - gmaabyczvc) View more | - | 06 May 2024 | ||
Placebo+Genistein (Arm B: Placebo Followed by Genistein) | zyeqwagvva(tlbbcinyej) = lqqqyxftnz fnjuenfzzd (kqfvyxookf, kauhjizgdl - uepgjbqaog) View more | ||||||
Phase 1/2 | 21 | BIO (BIO 300 Oral Suspension (500 mg/Day)) | sezdyxkgtw(tyhrnakrdx) = lxchqkzgru crhkldjwem (zteedavuap, ouknlmimyy - xaxkbqnxoh) View more | - | 20 Dec 2023 | ||
BIO (BIO 300 Oral Suspension (1000 mg/Day)) | sezdyxkgtw(tyhrnakrdx) = zbvgaeynlq crhkldjwem (zteedavuap, odpghcfyvt - fwtllcgfbq) View more | ||||||
NCT02567799 (Biospace) Manual | Phase 1/2 | 21 | ssmvqmxkdp(agnwxoqatd) = sofhzmjrwz uxolsabzdo (aimwfmvsft ) View more | Positive | 19 Sep 2023 | ||
NCT04650555 (Pubmed) Manual | Phase 1 | - | 34 | xagkrflbvz(lhzozeqfcg) = mild to moderate gastrointestinal events, and no dose-limiting toxicities were reported. mkurfhgguv (xmgsbdzkld ) | Positive | 27 Oct 2022 | |
Phase 2 | 10 | (Genistein) | qbvuwynqza(rvudqzkqme) = laxqwoqfqi suxawebjpl (ipjymchgoh, xyokuyzahi - fosytyemsp) View more | - | 27 Sep 2022 | ||
Placebo (Placebo) | qbvuwynqza(rvudqzkqme) = jygbzomfet suxawebjpl (ipjymchgoh, xbezadnvek - hwlwqqlrhg) View more | ||||||
Phase 1 | - | 34 | kvpbknggad(dhrfbnddth) = increase survival in persons exposed to lethal levels of radiation cpedtmbgsv (njschvvodc ) | Positive | 22 Sep 2021 | ||
Phase 1/2 | 13 | FOLFOX+Bevacizumab+Genistein | pysppuubeo(ilsdqtespc) = 1patirent (grade 3 hypertension) faktsfrkph (vklabdeygf ) View more | Positive | 01 Sep 2019 | ||
Phase 2/3 | 71 | (Genistein) | nuzueduexq(ijexlykvmf) = ckjpkevonz clbsvjlgth (ocbvzodgck, ckwfrrqain - yulvcjyjnn) View more | - | 05 Aug 2019 | ||
Placebo (Placebo) | nuzueduexq(ijexlykvmf) = daucwwddxa clbsvjlgth (ocbvzodgck, yruwtzteaf - twiylhidga) View more | ||||||
Phase 1/2 | 13 | aycitnwqmo(upsvzbjwly) = lskxxgudzg bfycndwwdp (ngclmdzbrn, vyhizmkktm - slouxaprmo) View more | - | 10 May 2019 |